Company News: Pfizer

Share this article:
Pfizer said last night that it suspended the osteoarthritis clinical program for investigational compound tanezumab following a certain number of reports that tanezumab patients had their osteoarthritis worsen leading to joint replacement. The product was being studied as a way to treat pain associated with the condition. Pfizer said the adverse event has not been observed in non-osteoarthritis patient populations taking tanezumab. Pfizer said the monoclonal antibody is still being studied in conditions such as cancer pain, low back pain and pain associated with diabetes.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters